The EORTC Soft Tissue and Bone Sarcoma Group (STBSG)
The objectives of the STBSG were to develop, stimulate and co-ordinate studies on all aspects of the treatment of soft tissue sarcomas (STS) as well as to organise congresses, symposia and conferences to promote these studies. Today the STBSG has members from 56 institutions from 14 countries.
Sarcoma Alliance For Research through Collaboration (SARC)
SARC is a non-profit organization dedicated to the development and support of clinical trial research for the prevention, treatment and cure of sarcomas - a cancer of the bone and connective tissue of the body. SARC was formed in 2003 by sarcoma specialists at five major medical facilities to achieve the necessary multidisciplinary level of collaboration required to achieve the desired outcome for sarcoma patients.
World Sarcoma Network (WSN)
The mission of the World Sarcoma Network (WSN) is to stimulate rapid clinical drug development for sarcomas and enable performance of clinical studies that a cooperative group could not complete on its own.
The WSN will
- serve as a communication and facilitation platform between cooperative sarcoma clinical research groups worldwide
- act as a common point of interaction with the pharmaceutical industry, advocacy and community groups and governments globally
- have a focus on clinical reseach and drug development
Read more about the World Sarcoma Network
European Musculo-Skeletal Oncology Society (EMSOS)
The Association, founded in 1987 in Italy. The aims of the Association are to advance the science and practice of the diagnosis and treatment of bone and soft tissue tumours, to promote basic en clinical research, and to disseminate knowledge in order to provide a common high standard of musculo-skeletal oncology. The particular purpose of the Association is to promote mutual collaboration between different specialists and institutes involved in the treatment of musculo-skeletal tumours.
EU Funded Projects
The consortium builds on the successful co-ordination of scientific excellence of Conticanet and EuroBoNeT FP6 NoEs, where most of the same partners were involved. The objective will be achieved through the development and conduct of 9 (2“Soft tissues” + 7“Bones”9 phase I/II and III) investigator-driven clinical trials in rare histological and molecular subtypes of sarcoma, through the establishment of an integrated consortium, gathering representatives of most European sarcoma groups, SME, all with proven track records of scientific and clinical excellence. These trials will be performed in close collaboration with patient advocacy groups, participating here as partners through the European network of patient advocacy groups, Sarcoma Patients EuroNet (SPAEN), developed during the FP6 Network of Excellence, „Conticanet“. Prof. Dr. Jean Yves Blay is EUROSARC‘s coordinator.
EuroBoNet is the first European Network of excellence dedicated to bone tumors seeking to integrate research among top notch bone sarcoma referral centers. Integration and optimization of technical platforms, diagnostic expertise and research skills represent the backbone of the consortium.
Launched in February 2006, CONTICANET is a Network of Excellence funded by the 6th Framework Program of the European commission. This network is generating a critical mass of key stakeholders in order to overcome the current difficulties in terms of lack of data, data fragmentation, mobility of researchers, heterogeneity of methodologies and legislation. CONTICANET is working to harmonise research projects, by developing joint research activities, establishing standard operating procedures and distributing databases and tissue banks.
RARECARE is co-funded by the European Commission (from 04/2007 to 03/2010) through its Public Health and Consumer Protection Directorate (DG SANCO), PHEA programme, and contributes among other projects to the creation of networks of action for rare diseases.